The annual rate of change for prescription pharmaceutical prices in the United States held at 3.4% in the third quarter of 1998, compared to the third quarter of 1997.
The annual rate of change for prescription pharmaceutical prices in the United States held at 3.4% in the third quarter of 1998, compared to the third quarter of 1997, according to IMS Health, Plymouth Meeting, PA.
The rate was unchanged from the second quarter, but some market segments showed significant changes.
Prices rose significantly for some generic products, for example, causing a marked reduction in overall price declines. The net overall generic price change in the third quarter was down 2.7%, representing "a major change in the pricing strategy for the generic marketplace," IMS Health noted.
This change caused a slight increase in prescription drug prices for the retail sector. They rose by roughly 4.3%, up from the annual rate of 3.9% reported in the second quarter.
"This increase in the retail sector is being driven by the slowing of price declines for generics," said Myron Holubiak, general manager of IMS Health's consulting division. "While prices of brand-name drugs in this sector remain unchanged from last quarter, generic drug prices decreased 3.2%. This is a significant change from the 6% declines seen in the past year."
In the non-retail sector, brand-name drug prices rose by a mere 1.1%, a rate considerably lower than the 2% increase recorded in the second quarter.
Overall, prescription sales volume grew by 12.4% for the third quarter versus the same period last year.
Prices accounted for less than one-third of total sales growth, as new products and line extensions drove the majority of the growth. Volume and mix categories accounted for the rest of the growth.
Holubiak said: "We maintain that new product sales - not just price increases - are driving growth." PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.